AB
ZNTL icon

Amalgamated Bank’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Amalgamated Bank’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,987
Closed -$3K – 3163
2025
Q1 		$3K Hold
1,987
– – ﹤0.01% 2814
2024
Q4 		$6K Hold
1,987
– – ﹤0.01% 2693
2024
Q3 		$7K Hold
1,987
– – ﹤0.01% 2652
2024
Q2 		$8K Hold
1,987
– – ﹤0.01% 2582
2024
Q1 		$31K Sell
1,987
-6,309
-76% -$86.8K ﹤0.01% 2000
2023
Q4 		$126K Sell
8,296
-188
-2% -$2.74K ﹤0.01% 1930
2023
Q3 		$170K Buy
8,484
+1,011
+14% +$25.7K ﹤0.01% 1840
2023
Q2 		$211K Buy
7,473
+947
+15% +$22.7K ﹤0.01% 1798
2023
Q1 		$112K Sell
6,526
-955
-13% -$19.3K ﹤0.01% 2010
2022
Q4 		$151K Hold
7,481
– – ﹤0.01% 1962
2022
Q3 		$162K Buy
7,481
+1,455
+24% +$39.8K ﹤0.01% 1932
2022
Q2 		$169K Buy
6,026
+81
+1% +$2.15K ﹤0.01% 1950
2022
Q1 		$274K Sell
5,945
-442
-7% -$23.8K ﹤0.01% 1805
2021
Q4 		$537K Buy
6,387
+6
+0.1% +$464 ﹤0.01% 1545
2021
Q3 		$425K Buy
6,381
+103
+2% +$5.94K ﹤0.01% 1669
2021
Q2 		$334K Buy
+6,278
New +$336K ﹤0.01% 1836
2021
Q1 		– Sell
-4,148
Closed -$215K – 1628
2020
Q4 		$215K Buy
+4,148
New +$187K 0.01% 1412

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

Amalgamated Bank's ZNTL Position: Q2 2025 in Review

Amalgamated Bank sold out of Zentalis Pharmaceuticals (ZNTL) in Q2 2025, closing a stake of 1,987 shares — an estimated $3K sold.

Amalgamated Bank first reported a position in ZNTL in Q4 2020 and held it in 17 quarters. The position peaked at $537K in Q4 2021. 117 funds tracked by Wall St. Rank hold ZNTL as of Q2 2025.

  • Amalgamated Bank reported no remaining Zentalis Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Amalgamated Bank sold 1,987 Zentalis Pharmaceuticals shares in Q2 2025, an estimated $3K.
  • Amalgamated Bank first reported a position in Zentalis Pharmaceuticals in Q4 2020 and held it in 17 quarters.
  • Amalgamated Bank's Zentalis Pharmaceuticals position peaked at $537K in Q4 2021.
  • 117 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2025.

Based on Amalgamated Bank's 13F filing for Q2 2025, filed 4 Aug 2025.